Dysregulated SIRT2 expression has been observed in multiple other cancers with clear clinical relevance, including renal cell carcinoma (RCC), gastric cancer, and melanoma, while SIRT2 appears downregulated in ovarian carcinoma and prostate cancer (Figure 1). Here, SIRT2 is linked to prostate cancer.